Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Conditions
Interventions
BGB-16673
Bendamustine
+3 more
Locations
115
United States
St Bernards Medical Center
Jonesboro, Arkansas, United States
UCLA Department of Medicine Hematologyoncology
Los Angeles, California, United States
Pih Health Whittier Hospital
Whittier, California, United States
Rocky Mountain Cancer Centers (Williams) Usor
Aurora, Colorado, United States
Florida Oncology and Hematology
Fort Myers, Florida, United States
Baptist Md Anderson Cancer Center
Jacksonville, Florida, United States
Start Date
April 10, 2025
Primary Completion Date
May 15, 2028
Completion Date
February 14, 2030
Last Updated
April 22, 2026
NCT07218341
NCT07523555
NCT07030400
NCT05006716
NCT07277231
NCT06859424
Lead Sponsor
BeOne Medicines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions